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Abstract 
Background: Hyperglycaemia has a powerful association with adverse prognosis for patients with acute 
coronary syndromes (ACS). Previous work shows high glucose prevents ischaemic preconditioning and 
causes electrical and mechanical disruption via PKCα/β activation.  
The aims of this study were to: 1) determine whether the adverse clinical association of hyperglycaemia in 
ACS can be replicated in preclinical cellular models of ACS. 2) Ascertain the importance of PKCα/β 
activation to the deleterious effect of glucose.   
Methods: Freshly isolated rat, guinea pig or rabbit cardiomyocytes were exposed to simulated ischaemia 
after incubation in the presence of normal (5mM) or high (20mM) glucose in the absence or presence of 
small molecule or tat-peptide-linked PKCαβ inhibitors. In each of the 4 conditions, the following hallmarks 
of cardioprotection were recorded using electrophysiology or fluorescent imaging: cardiomyocyte 
contraction & survival, action potential stability & time to failure, intracellular calcium & ATP, 
mitochondrial depolarisation, ischaemia-sensitive leak current and time to Kir6.2 opening.  
Results: High glucose alone resulted in decreased cardiomyocyte contraction and survival, however, 
imparted cardioprotection in the presence of PKCα/β inhibitors. This cardioprotective phenotype displayed 
improvements in all measured parameters and decreased myocardium damage during whole heart coronary 
ligation experiments.    
Conclusions: High glucose is deleterious to cellular and whole-heart models of simulated ischaemia, in 
keeping with the clinical association of hyperglycaemia with adverse outcome in ACS. PKCαβ inhibition 
revealed high glucose to show a cardioprotective phenotype in this setting. This study suggests the potential 
for therapeutic application of PKCαβ inhibition in ACS associated with hyperglycaemia.  
 
[3] 
 
Introduction  
Acute coronary syndromes (ACS) encompass a spectrum of acute myocardial ischaemia and 
injury, ranging from unstable angina and non-ST-segment elevation myocardial infarction, to ST-
segment elevation myocardial infarction (Yiadom, 2011). Current ACS therapies focus on restoring 
reperfusion to the ischaemic territory to salvage viable myocardium and prevent artery re-occlusion, 
and so improve the clinical outcome (Niccoli et al., 2015). Somewhat paradoxically, coronary artery 
reperfusion, while relieving ischaemia, has itself been associated with myocardial damage, an event 
which has been termed ‘myocardial reperfusion injury’ (Niccoli et al., 2015). Development of 
adjunctive therapies to reduce ischaemia and reperfusion injury have gained increasing attention, partly 
due to the inevitable logistical delay in restoring reperfusion in ACS (Lassen et al., 2013). While 
experimental evidence suggests that a number of pharmacological stimuli may be beneficial in reducing 
reperfusion injury, translation into clinical application has so far proved challenging (Schmidt et al., 
2014).   
Acute hyperglycaemia, acute elevations in blood glucose  often termed ‘stress hyperglycaemia’, 
is common in the setting of ACS, and is associated with adverse outcome, irrespective of a prior 
diagnosis of diabetes mellitus (Squire et al., 2010; Steg et al., 2012; Fujino et al., 2014). Even minor 
elevations of blood glucose (above 8.2mmol/l) have been associated with adverse impact on outcome 
after ACS (Squire et al., 2010; Gardner et al., 2015; Al Jumaily et al., 2015). The American Heart 
Association (AHA) (O’Gara et al., 2013), the National Institute for Health and Care Excellence (NICE) 
(Corbett, 2012) and the European Society of Cardiology (Steg et al., 2012) all acknowledge the 
importance of managing hyperglycaemia in patients with ACS. Despite this, hyperglycaemia remains 
underappreciated as a risk factor in ACS and is frequently untreated (Kosiborod & Deedwania, 2009). 
The AHA stated that more research is necessary to enhance the understanding of the relationship 
between elevated glucose and adverse outcomes, plus whether treatment of hyperglycaemia improves 
outcomes (Deedwania et al., 2008). 
The molecular mechanism of damage to the myocardium during ACS is a controversial area of 
the literature, however it is commonly acknowledged that disruption of mitochondrial function is a key 
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component. Overload of [Ca2+]i, dissipation of the mitochondrial membrane potential and low levels of 
ATP are proposed to lead to necrotic or apoptotic death via formation of the mitochondrial permeability 
transition pore (Nesci, 2018; Briston et al., 2019). This is proposed to lead to an efflux of reactive 
oxygen species (ROS) and cytochrome C into the cytoplasm, driving further release of ROS from the 
matrix of the mitochondrion, which propagates cellular damage across the microenvironment and 
initiates apoptotic signalling in the neighbouring cells (Penna et al., 2009). Hyperglycaemia has been 
suggested to exacerbate this injury by promoting mitochondrial membrane depolarisation in H9C2 cells 
(Kumar et al., 2012), whilst Su et al. suggested that there was an increase ROS generation, increased 
caspase activity and infarct area in the hyperglycaemic myocardium (Su et al., 2013). 
Ex vivo experiments have demonstrated the direct toxicity of elevated glucose concentrations 
to whole heart and isolated cardiomyocytes preparations. Acute hyperglycaemia to whole rat hearts 
prior to experimental ischaemia and reperfusion caused myocardial oxidative stress, apoptosis and 
cardiac contractile dysfunction (Mapanga et al., 2014). Recently, we reported the deleterious effects of 
elevated glucose to freshly isolated cardiomyocytes in a non-ischaemic setting (Sims et al., 2014). In 
short, elevated glucose caused electrical instability, disruption of Ca2+ homeostasis and decreased 
cardiomyocyte survival. These deleterious effects of elevated glucose were all attenuated by various 
protein kinase C α/β (PKC/β) inhibitors.  
This study aimed to determine whether elevated glucose has adverse effects on cardiomyocyte 
survival in cellular and whole heart models of ACS, and whether PKC/β inhibition could attenuate 
any such effect. We report a mechanism that may contribute to the clinically demonstrated deleterious 
effects of high glucose in patients with ACS. We show that PKC/β inhibition attenuates the deleterious 
effects of elevated glucose and reveals a metabolism-dependent cardioprotection to freshly isolated 
cardiomyocytes in against simulated ischaemia and whole-heart left coronary artery ligation. These data 
suggest that PKC/β inhibition as a potential therapeutic target in ACS.  
Materials and methods  
Ethical Approval: 
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Adult male Wistar rats (300–400 g, 12 – 14 weeks old, n = 102, bred in-house at the University of 
Leicester) or Dunkin-Hartley guinea pigs (up to 500 g, 12 – 14 weeks old, n = 8, purchased from Harlan 
UK), were killed by concussion and cervical dislocation. Rats and guinea pigs were maintained in 1800 
cm2 Tecniplast cages, using BED01/8 Dates and corn cob for bedding, housed in IVC caging (SPF free). 
The number of cage companions for the animals of 300–400 g is 5 based on a calculation of 350 cm2 
being required for each rat or guinea pig of that size. Experiments were also conducted on 
cardiomyocytes isolated from New Zealand white rabbit hearts (2.0–3.0 kg, 10 – 13 weeks old, n = 6, 
purchased from Envigo). Briefly, animals were pre-medicated with ketamine (Ketaset, 10 mg/kg, Fort 
Dodge, UK), medetomidine hydrochloride (Sedator, 0.2 mg/kg, Dechra, UK) and butorphanol 
(Torbugesic, 0.05 mg/kg, Fort Dodge, UK) (i.m.). Following stable sedation, animals were sacrificed 
with an overdose of sodium pentobarbitone (Euthetal, Rhone Merieux, UK; 111 mg/kg body weight, 
i.v.) containing Heparin (1000 IU, Multiparin, UK) delivered via the marginal ear vein.  The care and 
sacrifice of the animals conformed to the requirements of the U.K. Animals (Scientific Procedures) Act 
1986 (2012 amendment).  
Solutions: 
The normal Tyrode’s (NT) solution contained (in mM): 135 NaCl, 5 KCl, 0.33 NaH2PO4, 5 Na-
pyruvate, 10 4-(2-hydroxyethyl)-1-piperazineethanesulphonic acid (HEPES), 1 MgCl2 and 2 CaCl2 (pH 
7.4 with NaOH). Glucose was added to the solution as indicated in the text. Nominally Ca2+ -free 
Tyrode’s solution used during cardiomyocyte isolation was as outlined above with no added Ca2+. 
Substrate-free 2 mM Ca2+ Tyrode’s (SFT) contained, in mM, 140 NaCl, 5 KCl, 0.33 NaH2PO4, 10 
HEPES, 10 Sucrose 1 MgCl2 and 2 mM CaCl2 (pH 7.4).  
For all experiments, NT with 5 mM glucose was considered as the control glucose concentration as it 
is within the physiological fasting range (NICE guideline PH38). Clinically, hyperglycaemia is defined 
as a blood glucose concentration above 11 mM (NICE guideline [CG130]). To investigate the effects 
of raised glucose, NT solutions containing 10, 15, 20 and 30 mM glucose were used, and mannitol was 
used to ensure all Tyrode’s solutions were osmotically balanced. This range of glucose, although well 
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into the pathophysiological range, has been shown to be relevant to real clinical scenarios during MI 
(Squire et al., 2010). To ensure that the observations were due to changes in glucose a number of control 
experiments were conducted to control for osmolality. The pipette solution for whole-cell recording 
contained (in mM): 30 KOH, 5 EGTA, 110 KCl, 10 HEPES, 1 MgCl2, 0.61 CaCl2, 1 ATP, 0.1 ADP 
and 0.1 GTP, (pH 7.2 with KOH). For cell-attached patch recording, the solution contained (in mM): 
140 KCl, 10 HEPES, 0.5 MgCl2 and 1 CaCl2 (pH 7.4 with KOH). 
The protocol for isolation of ventricular cardiomyocyte was as described previously (Hudman & 
Standen, 2004; Rainbow et al., 2005; Sims et al., 2014; Brennan et al., 2015). For rat and guinea pig 
cardiomyocytes isolations, the heart was rapidly excised, temporarily placed into cold, nominally Ca2+-
free NT solution to stop contraction, and quickly cannulated via the aorta on a Langendorff type 
apparatus. Warmed Ca2+-free NT (37 °C) was then perfused through the heart in a retrograde fashion 
for 6 min to clear residual blood. Following this, the solution was exchanged for a Ca2+-free NT with 
enzyme mix (0.5 mg.ml-1 collagenase type II (Worthington, USA), 1.66 mg.ml-1 BSA from factor V 
albumin (Sigma-Aldrich, UK) and 0.6 mg.ml-1 protease (type XIV 15 % Ca2+; Sigma-Aldrich, UK) for 
8 – 15 min. The presence of rod shaped cardiomyocytes in the perfusate was used as an indication of 
digestion being complete. The solution was then exchanged for a 2 mM Ca2+ NT solution to inhibit the 
enzyme mix, the heart cut down and cardiomyocytes mechanically dispersed from the tissue in a 
shaking water bath at 37°C. Typically this method yielded 70 – 90 % rod-shaped cardiomyocytes, which 
were stored in NT solution at room temperature and used within 8 hr of isolating. Ischaemic 
preconditioning (IPC) was imparted to cardiomyocytes using a protocol involving 3 cycles of halted 
perfusion followed by re-perfusion (Rodrigo & Samani, 2008; Sims et al., 2014; Brennan et al., 2015). 
IPC cardiomyocytes were used up to 6 hr after isolation.  
For rabbit cardiomyoycte isolaton, the hearts were rapidly excised, placed into ice cold Ca2+-free 
Tyrode’s solution and then retrogradely perfused through the ascending aorta in conditions of constant 
flow Langendorff mode (40 ml/min). An enzyme solution, containing 1mg/ml Type II collagenase 
(Worthington), 0.66mg/ml Protease and 1.66 mg/ml Bovine Serum Albumin (essentially fatty acid 
free), was perfused for 8 minutes. Following this, the heart was perfused with NT for 3 minutes prior 
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to cutting the left ventricle away from the remaining tissue. Cells were mechanically dispersed as 
described for rat and guinea pig cardiomyocytes and used within 8 hr. 
Clinical data 
The clinical data presented in this paper were gathered during routine care of patients admitted with a 
diagnosis of acute STE segment elevation myocardial infarction (STEMI) as previouly been reported 
(Squire et al., 2010). The diagnosis required (i) EKG evidence of dynamic ST segment elevation 
together with (ii) appropriate symptoms and (iii) increase in serum levels of CK to greater than twice 
the upper limit of the laboratory reference range (ie >400 IU/L). Troponin concentrations were not 
available for the full study period. Although predating the Myocardial Ischaemia National Audit 
Project, our database is that used by our hospital for this purpose. In this context, data collection does 
not require individual patient consent. The project was approved by the local research ethics committee. 
Data are from consecutive admissions (1 January 1993 to 31 December 2005) to the coronary care unit 
of a large teaching hospital (Leicester Royal Infirmary). The blood glucose concentration used was that 
first recorded for the index admission, assayed as part of routine investigations.  
Simulated ischaemia and reperfusion models: 
Cardiomyocyte contraction and cell death was investigated using two different metabolic poisons.  1) 
Substrate-free metabolic inhibition Tyrode’s solution (SFT-MI; contained 2 mM cyanide to inhibit 
oxidative phosphorylation and 1 mM iodoacetic acid to inhibit GAPDH) (Rainbow et al., 2004; 
Hudman & Standen, 2004; Sims et al., 2014; Brennan et al., 2015). 2) Ischaemic buffer contained in 
mmol/L, 108 NaCl, 16 KCl, 0.33 NaH2PO4, 10 PIPES, 20 deoxyglucose, 20 Na-lactate, 1 MgCl2, 2 
CaCl2, and 0.2 2,4-dinitrophenol (DNP), pH 6.8 with NaOH) (Brennan et al., 2015). Cardiomyocytes 
were perfused at a rate of 5 ml.min-1 at 32°C, stimulated to contract via 1 Hz electric field stimulation 
(EFS) and contractile function observed via a JVC CCTV camera and recorded to DVD. The 
experimental protocol is shown in each figure. 
Patch Clamp Electrophysiology: 
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Conventional patch pipettes were used in the whole-cell configuration in either voltage-clamp or 
current-clamp mode to record metabolically sensitive “leak” current or action potentials, respectively. 
Recordings were made from isolated cardiomyocytes using an Axopatch 200B amplifier, digitized 
using a Digidata 1440 and recorded and analysed using pCLAMP 10.7 software (RRID:SCR_011323, 
Axon instruments, Scientifica, Uckfield UK).   
Fluorescent imaging: 
Cardiomyocytes were loaded with either Fura-2-AM (excitation 340:380 nm, emission collected >520 
nm), Magnesium Green (excitation 480 nm, emission collected >520 nM) or Tetramethylrhodamine 
methyl ester (TMRM) (excitation 546 nm, emission collected >560 nM) for 10-20 min to measure 
[Ca2+]i, intracellular [ATP] or mitochondrial membrane potential, respectively. Fluorescence was 
excited using a monochromator (PTI, Birmingham, NJ, USA) at 0.2 Hz for 40 ms to minimise 
photobleaching. Emissions were captured using a Cascade 512B CCD camera (Photometrics, Tuscan, 
AZ, USA) and processed using EasyRatioPro software (PTI, Birmingham, NJ, USA). 
Langendorff-perfused heart and coronary artery ligation.  
The heart was allowed to stabilize for 1 hr. The left anterior descending coronary artery was then ligated 
(40 min) to cause ischaemia by using 5-0 USP braided silk suture and two pipette tips to form a 
reversible knot around the artery (Figure 15A, second picture from left). The knot was then removed to 
start the 3-hr reperfusion phase with the suture remaining in place to allow for re-ligation (Figure 14A, 
third picture from left). During all phases temperature was carefully kept at 37°C by submerging the 
heart in Tyrode’s solution using a heated water jacket. Evans Blue dye (1% in Tyrode’s solution) and 
2,3,5-triphenyltetrazolium chloride (Sigma Aldrich) were used to identify area at risk (AAR) and 
infarcted area (IA), respectively. To determine the AAR and IA, each slice was scanned on both sides 
and weighed. AAR and IA were calculated for each of the slices from the heart using ImageJ. The AAR, 
IA and unaffected area sizes from ImageJ (RRID:SCR_003070) were then used to calculate the 
percentage infarct of the AAR by weight. 
Western blotting.  
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Hearts from an adult male Wistar rats (300 – 400 g) were rapidly excised and perfused for 30 min at 37 
°C on a Langendorff system with 5 mM glucose, 20 mM glucose or 5 mM glucose Tyrode’s solution 
with 1 M PMA. Hearts were then snap frozen in liquid nitrogen and stored at -80 °C. When required 
hearts were chopped and added to ice-cold lysis buffer (Tris-HCl pH 7.4, 20 mM; 1% (v/v) Triton X-
100, NaCl, 137 mM; EDTA, 2 mM, sodium orthovanidate; 1 mM; phenylmethanesulphonylfluoride, 
500 μM; leupeptin, 0.1 mg/mL; benzamidine, 0.2 mg/mL; pepstatin, 0.1 mg/mL).  Tissues were then 
homogenisation on ice using a Polytron PT210 homogeniser (Kinematica, Basel, Switzerland), prior to 
centrifugation at 1000 rpm to remove nuclear material. The resulting supernatant was removed and 
subjected to a further centrifugation step at 14,000 rpm to separate the cytosolic and membrane 
fractions. Once the cytosolic fraction was removed, the membrane pellet was re-suspended in lysis 
buffer and the protein content of all fractions determined by the Bradford method (Bradford, 1976). 
Samples were diluted to 1mg/ml by the addition of 2x sample buffer (250 mM Tris-HCl, pH 6.8, 0.01% 
bromophenol blue (w/v), 2% SDS (w/v), 40% (v/v) glycerol and 50 mM dithiothreitol). Samples were 
then boiled for 5 min before separation of 40 g of each sample on 10% SDS-PAGE gels, transferred 
to nitrocellulose and blocked using standard Western blotting techniques. Phospho PKC (ab76016; 
1:50,000) was detected using specific anti-rabbit antibodies (Abcam, Cambridge, UK), whilst total 
PKC or PKC (both 1:1000) were simultaneously detected using specific anti-mouse antibodies (BD 
Biosciences, Wokingham, UK). After incubation with secondary antibodies anti-rabbit IgG (H+L) 
DyLight 680-conjugate and anti-mouse IgG (H+L) DyLight 800-conjugate (Cell Signaling 
Technology), proteins were detected with infrared fluorescence using the Odyssey CLx imaging system 
(LI-COR, Cambridge, UK).  Protein expression was quantified by densitometry using Image J (version 
1.51, National Institutes of Health, Bethesda, MD) (RRID:SCR_003070). G protein coupled receptor 
kinase 2 expression was also determined using a mouse anti-GRK2 antibody (sc-13143; 1:1000; Santa 
Cruz, Biotech., CA, USA) using similar Western blotting techniques as described above.   
PKC inhibition 
Tat-linked PKC inhibitor peptides were used at a concentration of 100 nM as described previously 
(Rainbow et al., 2009; Sims et al., 2014; Brennan et al., 2015). Isolated cardiomyocytes were pre-
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incubated for 10 min with Tat-linked peptides, or the Tat-peptide with no linked peptides as a control, 
prior to experimentation. PKCα and β were also pharmacologically inhibited in isolated cardiomyocytes 
using Gö 6976 (300 nM: Tocris, Bristol, UK) and LY 379196 (300 nM; a kind gift from Eli Lilly, 
Indianapolis, USA). Tat-Linked peptides were soluble in water, however other drugs required to be 
diluted from stock solutions in DMSO. The maximum DMSO concentration was 0.1%. Equivalent 
volumes of vehicle (DMSO) had no effect on cardiomyocyte function in these experiments.  
Statistical analyses: 
All patch clamp data were analysed using pCLAMP10.7 (RRID:SCR_011323) and Microsoft Excel 
2016 (RRID:SCR_016137) software. Calcium, MgGreen and TMRM imaging data were analysed using 
WinFluor4.0.2 (Dr John Dempster, University of Strathclyde). Contractile function data were analysed 
in Microsoft Excel. All figures were made in Graphpad Prism 7 (RRID:SCR_002798) and statistical 
analysis was performed in Prism 7 as indicated in the text. 
 
Results  
Elevated glucose is deleterious to cardiomyocyte function and viability during simulated 
ischaemia.  
Acute hyperglycaemia, which may result from stress, is common among AMI patients, 
irrespective of prior diabetes status, and is associated with poor outcome. Figure 1A&B show the 
distribution of blood glucose concentration at the time of admission from 3854 non-diabetic or diabetic 
AMI patients. A large proportion (>48%) of patients without a prior diagnosis of diabetes have a blood 
glucose of >8 mM. Previous reports have shown that, irrespective of diabetic status, a blood glucose 
concentration of >8 mM is associated with poor outcome for AMI patients (Squire et al., 2010; Timmer 
et al., 2011; Steg et al., 2012; Fujino et al., 2014; Gardner et al., 2015; Al Jumaily et al., 2015). From 
these data, 20 mM glucose was deemed sufficient to investigate, using cellular and whole-tissue AMI 
models, the damage caused by acute glucose and the therapeutic potential of mechanisms that may 
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remove any glucose-induced deleterious effect. In this study, the effects of acutely elevated glucose at 
the time of AMI was investigated using tissues from non-diabetic animals.  
We previously described the deleterious effects of elevated glucose to freshly isolated 
cardiomyocytes in non-ischemic conditions (Sims et al., 2014). To determine whether high glucose also 
impacts the viability, or survival, of cardiomyocytes during and after simulated ischaemia and 
reperfusion, cardiomyocytes were exposed to a range of glucose concentrations prior to, and following, 
simulated ischaemia. In accordance with our previous findings (Sims et al., 2014), elevated glucose 
significantly reduced the proportion of rod-shaped cardiomyocytes maintaining contractile function at 
the beginning of the experiment (Figure 1C). Using two different simulated ischaemia protocols, raised 
glucose, in a concentration-dependent manner, decreased the percentage of cardiomyocyte contractile 
recovery and cell survival in both metabolic poisons used (Figure 1, SFT-MI & Figure 2, Ischaemic 
Buffer (Brennan et al., 2015)). The ischaemic buffer also lead to arrhythmic contractions upon 
reperfusion, presumably due to the buffer’s high potassium content, which increased in frequency in 
20G (Figure 2B and F). These findings were not confined to rat cardiomyocytes; observations were 
similar using freshly isolated guinea pig (Figure 3A-C) and rabbit (Figure 4A-C) cardiomyocytes. 
Combined these data suggest, in accordance with the clinical literature (Squire et al., 2010) and our 
previous work (Sims et al., 2014), that elevated glucose is deleterious to cardiomyocyte function and 
viability after simulated ischaemia.   
 
Elevated glucose is cardioprotective in the presence of PKCα/β inhibition during simulated 
ischaemia 
Our previous publication demonstrated that the deleterious effects of high glucose on 
cardiomyocytes in a non-ischemic setting were PKCα/β dependent (Sims et al., 2014). The aim of the 
present study was to ascertain whether PKCα/β activation was also responsible for the deleterious 
outcome of high glucose during simulated ischaemia. PKCα/β were inhibited using both 
pharmacological (300nM Gö6976 or LY379196) and peptide (Tat-PKC20-28, Tat-PKCα and Tat-
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PKCβ) inhibitors. The proportion of rod-shaped cardiomyocytes contracting at the beginning of the 
experiment in 20G was increased by each PKCα/β inhibitor used, comparable to our previous findings 
(Sims et al., 2014) (Figure 5A). The contractile recovery and survival of cardiomyocytes in 20G at the 
end of the simulated ischaemia protocol was enhanced by pre-incubation with any PKCα/β inhibitor 
(Figure 5B-C, p<0.001). Notably, activation of the well-established effector of cardioprotection, PKCε, 
was not responsible for the cardioprotection observed as the Tat-PKCε inhibitor did not abolish the 
cardioprotective effect. Furthermore, when using the ischaemic buffer protocol, Gö6976 also revealed 
a cardioprotective effect of high glucose in experiments and caused a significant decrease in arrhythmic 
contractions seen in 5G or 20G alone (Figure 2). Gö6976 also revealed a glucose-dependent protection 
in freshly isolated guinea pig (Figure 3D-F) and rabbit (Figure 4D-F) cardiomyocytes. These data 
suggest that PKCα/β inhibition prevents the deleterious effects associated with elevated glucose, and 
additionally reveals a cardioprotective effect of high glucose during simulated ischaemia.  
 
Elevated glucose causes an increase in phosphorylated PKCα translocation to the membrane. 
To determine whether glucose was able to active PKC, western blotting of total and phospho-
PKCα in whole heart lysates was carried following 30 min of pre-treatment with 5 mM, 20 mM and 5 
mM glucose with 1 M PMA. In both 20 mM glucose and PMA-treated hearts, the phosphorylated 
PKCα was increased compared to 5 mM glucose control hearts (Figure 6). PKC was not translocated 
to the membrane fraction in 20 mM glucose, suggesting it was not activated by elevated glucose. GRK2 
is a cytosolic protein which is recruited to the plasma membrane upon ligand activation of G protein-
coupled receptors. Under resting conditions, most of the kinase is found in the cytoplasm, thus, to 
confirm successful fractionation, the relative distribution of GRK2 was examined. Reassuringly, strong 
GRK2 expression was observed in all the cytosolic fractions with only minimal levels detected in the 
membrane fractions. In addition, glucose treatment did not recruit GRK2 to the membrane, further 
highlighting the glucose-dependent selective recruitment of PKCα. 
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Both deleterious and cardioprotective effects of elevated glucose are mediated via glycolytic 
metabolism  
To determine whether the effects of 20G were dependent on glycolytic metabolism, 
cardiomyocyte function was investigated in the presence of the non-metabolised enantiomer of glucose, 
L-glucose, which acts as a competitive glycolytic metabolic inhibitor. L-glucose (10mM) attenuated 
both the deleterious (Figure 7A; p<0.05) and the cardioprotective (+300nM Gö6976; Figure 3A&B; 
p<0.001) effect of 20G on contractile recovery and cell survival. These results imply that competitive 
inhibition of glycolytic metabolism reduces both the deleterious and the revealed cardioprotective effect 
(+PKCα/β inhibition) of 20G. A role for glycolytic metabolism was further supported by experiments 
altering the amount of pyruvate or substituting fructose for glucose. In a concentration-dependent 
manner, both metabolized sugars, glucose and fructose, caused decreased contractile recovery and cell 
survival. However, both sugars elicited a concentration-dependent cardiomyocyte protection upon 
PKCα/β inhibition with Gö6976 (Figure 7C-F). Similar results were obtained whether the solutions 
used were osmotically balanced by the non-metabolized sugar mannitol or in the absence of any osmotic 
balance (Figure 7G-I), suggesting changes in osmolality were not responsible for the observations. 
Collectively, these data suggest that both the harmful effects caused by 20G, and the cardioprotection 
from 20G revealed by PKCα/β inhibition during simulated ischaemia are dependent on glycolytic 
metabolism. 
 
In the presence of 20G, Gö6976 delays time to action potential failure during simulated ischaemia 
and attenuates variation of APD90.  
We have previously shown that 20G causes perturbation in electrical signalling and disruption 
of intracellular calcium homeostasis (Sims et al., 2014). Fluorescent imaging and electrophysiology 
were employed to establish whether the protection against simulated ischaemia by 20G and the PKCα/β 
inhibitor Gö6976 was caused by changes in electrical excitability.  
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Using electrophysiology to measure action potentials, during simulated ischaemia, 
cardiomyocytes perfused with 20G, but not with 5G (Figure 8A), displayed early after depolarisations 
(EADs), which were prevented by Gö6976 (Figure 8B). The EAD caused by 20G resulted in variation 
in the action potential duration to 90% repolarized (APD90) before and during simulated ischaemia; this 
was prevented by Gö6976 (Figure 8C). The extent of APD instability can be visualised by means of the 
Poincaré plot of the mean APD90 vs mean APD90+1. In such a plot, identical action potentials project to 
a single point. Figure 4 shows that in all conditions other than 20G without Gö6976, APD90 was stable 
during SFT-MI. These data suggest that the EADs and APD variation caused by 20G are dependent on 
PKCα/β activation. 
Prolonged perfusion with SFT-MI resulted in cardiomyocyte action potential failure (Figure 
8Ci-ii); however, this was delayed by Gö6976 with 20G (Figure 8E; p<0.001). As cardioprotective 
stimuli delay the time to action potential failure (Brennan et al., 2015), these data suggest PKCα/β 
inhibition in high glucose is cardioprotective . 
 
Cardiomyocytes in the presence of elevated glucose and PKCα/β inhibition display the classical 
hallmarks of a cardioprotective phenotype. 
Our previous work has shown that well-characterised cardioprotective stimuli (i.e. Adenosine 
and ischaemic preconditioning) preserve efficient calcium handling, intracellular ATP and 
mitochondrial function which, in turn, delays the activation of a metabolic sensitive leak current caused 
by the opening of sarcolemmal ATP-sensitive (Kir6.2/SUR2A) potassium (KATP) channel (Brennan et 
al., 2015). A combination of fluorescent imaging and electrophysiology was used to determine whether 
these hallmarks of a cardioprotective phenotype were observed in conditions of elevated glucose with 
PKCα/β inhibited.  
The emitted fluorescence of the Fura-2, Mg-Green or TMRM loaded cardiomyocytes increased during 
the simulated ischaemia protocol in all experimental conditions (Figure 9 and 10), indicative of 
increased intracellular calcium, decreased ATP and mitochondrial depolarisation, respectively. In the 
absence of Gö6976, the Fura-2 ratio and Mg Green fluorescence increase at the end of the protocol was 
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greater in cardiomyocytes exposed to 20G compared to 5G. Gö6976, however, attenuated the Fura-2 
ratio and TMRM fluorescence increase in cardiomyocytes exposed to 20G (Figure 9 and 10). The 
preservation of intracellular ATP can also explain the delayed opening of the sarcolemmal ATP-
sensitive (Kir6.2/SUR2A) potassium (KATP) channel and metabolic sensitive leak current in 20G with 
Gö6976 (Figure 11). These data suggest that PKCα/β inhibition reveals a protective effect of 20G, 
which display all the hallmarks of a cardioprotective phenotype usually associated with established 
cardioprotective stimuli such as adenosine (Brennan et al., 2015).  
Gö6976 and LY379196 applied at any phase of simulated ischaemia protects cardiomyocytes in 
the presence of elevated glucose. 
Pre-incubation of PKCα/β inhibitors prior to the simulated ischaemia protocol revealed a 
cardioprotective effect of 20G (Figure 5). To consider the potential clinical application of PKCα/β 
inhibition in treatment of ACS, Gö6976 (Figure 12A-C) or LY379196 (Figure 12D&F) were applied at 
the start of either the simulated ischaemia or reperfusion phase to closely mimic the likely therapeutic 
scenario. In the presence of 20G, either PKCα/β inhibitor increased cardiomyocyte contractile recovery 
and survival when applied during SFT-MI or at reperfusion (Figure 12B-F, p<0.001). Furthermore, 
when glucose was only elevated at reperfusion, to simulate stress-induced hyperglycaemia, both drugs 
improved contractile recovery and survival (Figure 12, p<0.001).  
Gö6976 with high glucose imparts cardioprotection during whole heart coronary ligation 
 Left anterior descending (LAD) coronary artery ligation to whole hearts perfused, on an ex vivo 
Langendorff preparation, was used to determine whether PKCα/β inhibition could impart protection to 
whole tissue. As expected, perfusion with 20G lead to more damage to the myocardium compared to 
5G control (p<0.001), however, the presence of Gö6976 with 20G decreased the damage to the 
myocardium (Figure 14, p<0.05).  
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Discussion  
The association between elevated blood glucose at admission with ACS and subsequent adverse 
prognosis is well established (Squire et al., 2010; Fujino et al., 2014; Gardner et al., 2015; Al Jumaily 
et al., 2015). While national and international guidelines suggest consideration should be given to active 
management of elevated glucose in ACS, only a minority of cases receive such treatment (Kosiborod 
et al., 2005; Weston et al., 2007; Steg et al., 2012; Corbett, 2012; O’Gara et al., 2013). This apparent 
clinical inertia is likely to stem at least in part from the lack of a clear mechanism by which elevated 
glucose might be directly harmful to cardiomyocytes. The current study provides such evidence of such 
a mechanism.  
We previously reported toxicity from elevated glucose to isolated cardiomyocytes (Sims et al., 
2014) and augmented agonist-induced vasoconstriction vascular smooth muscle (Jackson et al., 2016), 
via PKCα/β activation. The current report shows that elevated glucose exerted toxicity to isolated 
cardiomyocytes in simulated ischaemia via PKCα/β activation. Unexpectedly, we observed that not 
only did PKCα/β inhibition attenuate glucose-mediated cardiotoxicity, it in fact imparted protection 
from simulated ischaemia to cardiomyocytes in elevated glucose. Analogous results were obtained 
across all three species tested (rat, guinea pig and rabbit) and in either model of simulated ischaemia 
used. The protection displayed all the classical hallmarks of known cardioprotective stimuli, including 
improved calcium handling and contractile recovery (Figure 15).  
Putative mechanisms for glucose-induced damage have concentrated on ROS generation, 
advanced glycation end products (AGES), sympathetic drive, and the potential for de novo DAG 
synthesis from a backup of glycolytic metabolites (Brownlee, 2001; Shah & Brownlee, 2016). The 
absolute mechanism of glucose-induced damage of the myocardium is unclear, however our findings 
in this study demonstrate a clear relationship between glucose, activation of PKCα/β and electrical 
disturbances in the myocytes. Importantly, our findings occur with acute not prolonged elevations of 
glucose. From this it is possible to at least limit the role of AGEs in the process that we observe as these 
are only formed following prolonged hyperglycaemia. Similarly, the polyol pathway is also unlikely to 
be part of this acute mechanism. 
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Our observations indicate a potential mechanism by which the established clinical association 
between acute hyperglycaemia during acute coronary artery ischaemia with adverse outcome may be 
mediated. Elevated extracellular glucose had clear deleterious effects on freshly isolated 
cardiomyocytes ex vivo. The similar findings on whole heart preparations confirm similar findings in 
prior reports (Mapanga et al., 2014). These models are free from the influence of potential confounding 
factors seen in vivo, such as sympathetic nervous system and vasoconstrictor hormone activation. We 
suggest our findings provide evidence of a mechanism by which hyperglycaemia may be directly toxic 
to cardiomyocyte integrity and function in the setting of ischaemia, and suggests that the clinical 
association between hyperglycaemia and adverse outcome after ACS may be the result of direct toxicity 
rather than an epiphenomenon.  
Hyperglycaemia is a known activating signal for cardiac PKC isozymes that modulate a variety 
of cellular events including apoptosis (Malhotra et al., 2005a). Previous papers have shown that 
inhibition of PKCβI/βII, -δ (delta) (Shizukuda et al., 2002) and ζ (zeta) all attenuate the 
hyperglycaemia apoptosis signal while ε (epsilon) inhibition has no effect,  however, PKCε activation 
prevents hyperglycaemia-induced apoptosis (Malhotra et al., 2005b). This study demonstrates that 
elevated glucose is cardioprotective in the presence of either of the small molecule (Gö6976 and 
LY379196) or peptide PKCα/β inhibitors. Importantly, these PKCα/β inhibitors imparted protection to 
cardiomyocytes when added either at the start of the simulated ischaemia or at the reperfusion phase. 
In all experimental protocols in this study, the cardioprotective phenotype was revealed in the presence 
of both high glucose and PKCα/β inhibition; neither glucose or PKCα/β inhibition used separately 
caused cardioprotection. Furthermore, the use of the two-way ANOVA throughout demonstrated a 
significant interaction between high glucose and PKCα/β inhibition. The potential importance and 
usefulness of such a treatment is underlined by findings demonstrating that elevated glucose ablates the 
cardioprotection imparted by ischemic preconditioning (IPC) and pharmacological agents (Kersten et 
al., 1998; Yang et al., 2013; Yu et al., 2014; Sims et al., 2014). Collectively, these reports raise the 
possibility that PKCα/β inhibitors may have therapeutic potential in ACS complicated by elevated blood 
glucose by imparting cardioprotection and attenuating the deleterious effects of elevated glucose. 
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Indeed, our findings suggest the potential for therapeutic elevation of blood glucose with concomitant 
PKCα/β inhibition. Moreover, PKCα/β inhibition may represent an alternative strategy by which to 
attenuate the adverse effects of hyperglycaemia in patients with ACS, in comparison to the current use 
of intravenous insulin; as with hyperglycaemia, hypoglycaemia is also associated with adverse outcome 
in ACS (Svensson et al., 2005). Therefore, intrinsic cardioprotection, and exogenous cardioprotective 
stimuli, may be ineffective if hyperglycaemia remains untreated. PKCα/β inhibition may provide a 
novel therapy to confer cardioprotection, whilst preventing hypoglycaemia caused by glucose lowering 
interventions. In the absence of any specific PKC inhibitors currently available to clinicians, it is 
possible that the use of Gq-receptor blockers, such as the angiotensin receptor blocker (ARB) Losartan, 
could be of benefit to reduce PKC activity indirectly. A study has shown that changes in cardiomyocyte 
phenotype with chronic hyperglycaemia in a streptozotocin model of diabetes were ablated by co-
treatment with Losartan (Alfarano et al., 2011). Our own previous work demonstrated that enhanced 
vasoconstriction in high glucose could be attenuated by specific PKC inhibition (Jackson et al., 2016). 
It is plausible that ARB’s could be administered to indirectly reduce PKC-mediated, hyperglycaemia-
induced, potentiation of vascular contractile signalling, as well as AT-II-dependent PKC activity in 
cardiomyocytes, at the time of ACS.    
The PKCβ inhibitor, Ruboxistaurin, an LY379196 analogue, is currently in phase I/II 
evaluation for treatment of heart failure. Various, pre-clinical studies have suggested PKCβ inhibition 
as a potential therapeutic target in heart failure via several mechanisms (Ferreira et al., 2011). 
Nevertheless, the Ruboxistaurin clinical trials demonstrate that PKCα/β inhibitors can be well tolerated, 
and may provide a novel therapeutic strategy in the treatment of ACS. This study adds to the growing 
evidence that PKCα/β inhibitors could be useful during ACS via a number of different mechanisms. 
PKCα promotes thrombus formation, however, mice lacking PKCα do not have a bleeding tendency 
suggesting PKCα as a possible antithrombotic target (Harper & Poole, 2010) while PKCα/β inhibition 
has also been reported to prevent elevated glucose-potentiation of agonist-induced vasoconstriction of 
pig coronary and human internal mammary arteries (Jackson et al., 2016). Furthermore, PKCα/β 
inhibition could potentially be beneficial irrespective of diabetes status as inhibition of PKCβ2 
[19] 
 
overexpression reduces myocardial ischaemia/reperfusion injury in diabetic rats (Liu et al., 2015). This 
study demonstrated that PKCα/β inhibitors with elevated glucose revealed a cardioprotective phenotype 
in cellular and a whole-heart model of ACS. Combined these data suggest that the therapeutic potential 
of PKCα/β inhibitors in ACS warrants further investigation.   
 
Study Limitations 
Our observations were performed ex-vivo and should not be extrapolated directly to the clinical 
setting without further investigation. PKCα/β activation is one mechanism by which elevated glucose 
may cause harm to cardiomyocytes and by inference to whole heart function in ACS. However, 
numerous studies have reported the deleterious effects of hyperglycaemia on the ischaemic myocardium 
through oxidative stress, inflammation, apoptosis, endothelial dysfunction, hypercoagulation and 
platelet aggregation (Ishihara, 2012).  
This study investigated the effects of acute hyperglycaemia in cellular and whole heart models 
of ACS, using tissue from non-diabetic animals. Acute hyperglycaemia (or stress-induced 
hyperglycaemia) is common amongst ACS patients hospitalised irrespective of a known diabetic status 
(Squire et al., 2010). However, the mechanisms behind myocardial damage or protection may be 
different in patients with, compared to those without, diabetes; an issue that will require investigation 
in appropriate animal models and human population. Recent findings in cardiomyocytes isolated from 
a streptozotocin model of hyperglycaemia suggested that there was a delay in the time to contractile 
failure, ATP-depletion and KATP channel activation during metabolic inhibition compared to 
normoglycaemia (Alfarano et al., 2011). In this study, the authors suggested that this delay was 
cytotoxic, placing an increased workload on the heart during ischaemia, however they also report that 
their diabetic cardiomyocytes were able to survive the metabolic inhibition more readily. These findings 
of a protected state mirror our data in high glucose, however only in the presence of PKC inhibition. 
The authors also report differences in glycogen store levels and glycolytic enzyme activity, both being 
higher in the cardiac cells isolated from the diabetic animals compared to normoglycaemic. These 
differences in phenotype suggest adaptation to chronic hyperglycaemia and therefore highlights the 
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importance of considering the effects of acute hyperglycaemia that can be induced in patients suffering 
ACS.      
   In summary, elevated glucose during ischaemia elicits deleterious effects on isolated 
cardiomyocyte function and whole heart function via a mechanism dependent upon glycolytic 
metabolism and PKCα/β activation. However, PKCα/β inhibition allows elevated glucose to impart 
protection against ischaemia. PKCα/β inhibition represents a potential therapeutic target in protecting 
the myocardium during ACS. 
 
Translational perspective 
Here, we demonstrate a mechanism by which elevated extracellular glucose augments the toxicity of 
simulated ischaemia and reperfusion on isolated cardiomyocytes, via activation of protein kinase C 
(PKC) α and β isoenzymes. We show that PKCα/β inhibition blocks this phenomenon and reveals 
elevated glucose to protect cardiomyocytes from ischaemia. Acute hyperglycaemia has a powerful 
association with adverse prognosis for patients with acute coronary syndromes (ACS). Our findings 
have implications for PKCα/β inhibition as a potential therapeutic target in ACS. Selective PKCα/β 
inhibition may, therefore, have potential to be a therapeutic directed towards reducing myocardial injury 
in ACS such as myocardial infarction. Given that aggressive treatment of hyperglycaemia with current 
glucose lowering therapies runs the risk of cause equally damaging hypoglycaemia, PKCα/β inhibition 
may provide a unique alternative to remove the cardiotoxicity of acute hyperglycaemia.  
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Figure 1 
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Figure 1. Glucose is elevated in AMI patients and augments the cardiotoxic effect of simulated 
ischaemia and reperfusion in cellular AMI models. Relative frequency histogram (A) and raw values 
(B) of blood glucose concentration, at the time of admission, in non-diabetic or diabetic AMI patients. 
(C) SFT-MI protocol showing example photographs of cells prior to metabolic inhibition, at the end of 
metabolic inhibition and at the end of the reperfusion phase. (D) example recordings to two cells using 
video edge detection measurements, top trace showing no contractile recovery on reperfusion and the 
bottom trace showing recovery. To the right are 30 s expanded sections of the trace showing individual 
contractions as downwards deflections representing the rhythmic shortening of myocytes. Traces and 
images 1 – 4 show (1) control contraction, (2) contractile failure, (3) end of metabolic inhibition and 
(4) end of simulated reperfusion. Traces 5 and 6 show (5) control contractions and (6) recovery of 
contractions in the recovering cell. (E) Time-course showing the percentage of contractile rod-shaped 
cardiomyocytes during SFT-MI protocol with various glucose concentrations as indicated. Histograms 
showing percentage contractile recovery (F) and cell survival (G), confirmed by Trypan Blue labelling) 
after 10 min reperfusion in various glucose concentrations (*P<0.05, ***P<0.001; One-Way ANOVA 
with Holm-Šídák post-test). n≥91 cardiomyocytes, 6 experiments, ≥3 animals for each data set. 
Experimental design used shown above the data. 
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Figure 2 
 
 
Figure 2: Gö 6976 reveals a glucose dependent cardioprotection against the damage caused by an 
ischaemic buffer. (A) example video edge detection recording from a single cardiomyocyte exposed 
to the ischaemic buffer and reperfusion. Expanded traces show 30 s of recording in (1) control 
conditions, (2) contractile failure, (3) on reperfusion where contraction resumes in all cells, (4) 
arrhythmias, not synchronous with EFS and (5) cell death (identified by Trypan blue staining. (B) Time-
course showing the percentage of contractile rod-shaped cardiomyocytes (B) or arrhythmic cells (C) 
during ischaemic buffer protocol.  Three conditions shown are in 5 and 20 mM glucose plus 20 mM 
glucose after pre-incubation with Gö 6976. Histograms depict percentage contractile recovery (D), Cell 
Survival (E), the time to contractile failure (F) and percentage arrhythmic cells (G) after the ischaemic 
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buffer protocol. *P<0.5 **P<0.01, ***P<0.001, One-Way ANOVA with Holm-Šídák post-test. n≥126 
cardiomyocytes, 6 experiments, from ≥3 animals for each data set. Experimental design used shown 
above the data. 
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Figure 3 
 
 
Figure 3: Gö 6976 reveals a glucose-dependent cardioprotection in guinea pig cardiomyocytes. A) 
Time-course showing the percentage of contractile rod-shaped cardiomyocytes during I/R protocol in 
various concentrations of glucose. Histograms showing percentage contractile recovery (B) and 
percentage cell survival (C) after 10 min reperfusion in various glucose concentrations. Graphs D-F 
show the same data as above but with the addition of a 10 min Gö 6976 pre-incubation period (*P<0.05, 
**P<0.01, ***P<0.001; One Way ANOVA with Holm-Šídák post-test). n≥90 cardiomyocytes (6 
experiments) from ≥3 animals for each data set. Experimental design used shown above each data set. 
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Figure 4  
 
Figure 4: Gö 6976 reveals a glucose-dependent cardioprotection in rabbit cardiomyocytes. A) 
Time-course showing the percentage of contractile rod-shaped cardiomyocytes during I/R protocol in 
5 or 20 mM glucose. Histograms showing percentage contractile recovery (B) and percentage cell 
survival (C) after 10 min reperfusion in 5 or 20 mM glucose. Graphs D-F show the same data as 
above but with the addition of a 10 min Gö 6976 pre-incubation period (*P<0.05, **P<0.01, 
***P<0.001; Unpaired T-test ). n≥83 cardiomyocytes (6 experiments) from ≥3 animals for each data 
set. Experimental design used shown above each data set.  
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Figure 5 
 
 
Figure 5. PKCα/β inhibition reveals a glucose-dependent cardioprotective mechanism. A) Time-
course showing the percentage of contractile rod-shaped cardiomyocytes during SFT-MI protocol in 
20G (control) and with pre-incubation of the inhibitors as indicated in figure. Histograms depict 
percentage contractile recovery (B) and cell survival (C) after SFT-MI in 20G or with pre-incubation 
of the inhibitors (***P<0.001, One-Way ANOVA with Holm-Šídák post-test). n≥82 cardiomyocytes, 
≥5 experiments, ≥3 animals for each data set. Experimental design used shown above the data.  
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Figure 6  
 
Figure 6: High glucose treatment causes increased PKC recruitment to cardiomyocyte 
membranes. Hearts were treated with 5 or 20 mM glucose or PMA (1 M) for 30 min. After treatment 
tissues were homogenised and separated into cytosolic and membrane factions. Lyates were subjected 
to SDS-PAGE separation and probed for phospho-PKC total PKC and total PKC. Representative 
immunoblots (A) and cumulative data (means ± SEM; for n = ≥3 hearts per treatment) show the effects 
of glucose and PMA on the cellular distribution of phospho-PKC (B), total PKC (C) and PKC (D). 
High glucose (20 mM) and PMA increased the recruitment of PKC and phosphor PKC to the 
membrane fraction but not PKCε (*p<0.05; one-way ANOVA, Dunnett’s post hoc test). Lysates were 
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also probed for GRK2 expression. Representative immunoblot (A) and cumulative data (B) (means ± 
SEM; for n = ≥3 hearts per treatment) show the effects of glucose and PMA on the cellular distribution 
of GRK2. High glucose (20 mM) does not promote GRK2 recruitment to the membrane fraction. 
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Figure 7 
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Figure 7: Gö 6976 imparts cardioprotection via a metabolism dependent pathway. Histograms 
depict percentage contractile recovery (A) and cell survival (B) after SFT-MI in 20G in the presence or 
absence of 300nM Gö6976 with or without 10mM L-glucose (*P<0.05, **p=P<0.01, ***P<0.001, 
Two-Way ANOVA with Holm-Šídák post-test). n≥87 cardiomyocytes, >3 experiments, ≥3 animals for 
each data set. Concentration-response curves showing percentage contractile recovery (C) and 
percentage cell death (D) with increasing glucose + 5 or 0.5 mM pyruvate in the absence (circles) or 
presence (triangles) of 300 nM Go 6976. Concentration-response curves showing percentage contractile 
recovery (E) and percentage cell death (F) with increasing fructose with 5 mM pyruvate in the absence 
(circles) or presence (triangles) of 300 nM Go 6976. The line on each graph represents the Hill equation 
fit to the data. n≥86 cardiomyocytes (6 experiments) from ≥3 animals for each data set. (G) Time-course 
showing the percentage of contractile rod-shaped cardiomyocytes during I/R protocol in various 
conditions including metabolizable and non- metabolizable sugars. Histograms showing percentage 
contractile recovery (H) and percentage cell survival (I) after 10 min reperfusion in the various 
conditions tested (**P<0.01, ***P<0.001; One Way ANOVA with Holm-Šídák post-test). n≥111 
cardiomyocytes, 6 experiments from ≥3 animals for each data set. Experimental design used shown 
above each data set. 
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Figure 8 
 
 
Figure 8: Glucose-induced perturbation in electrical signalling during simulated ischaemia in rat 
cardiomyocytes is attenuated by Gö6976. Example action potentials during simulated ischaemia 
recorded from rat cardiomyocytes in 5G (Ai) and 20G (Aii) without and with Gö6976 (Bi-ii). C) Mean 
change in AP duration to 90% repolarization (APD90) after perfusion in 5G or 20G without (i) and with 
(ii) 300 nM Gö6976. Arrows indicate time=0, the point at which SFT-MI was perfused on to 
cardiomyocytes. D) Poincaré plot showing the average APD90 for the first 120 APs during SFT-MI in 
the four conditions. E) Mean time to AP failure in SMT-MI in the four conditions (***P<0.001 Two-
Way ANOVA with Holm-Šídák post-test). n≥8 cardiomyocytes, ≥3 animals for each data set. 
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Figure 9 
 
Figure 9: Gö6976 attenuates the glucose-mediated deleterious effects of intracellular calcium 
accumulation in rat cardiomyocytes during simulated ischaemia. Time-courses showing the Fura-
2 ratio during SFT-MI protocol in 5G or 20G without (-) and with (+) Gö6976 (A-D). Cells were 
stimulated to contract by EFS throughout the protocol. Ca2+ transients were recorded at the beginning 
(+) and end (#) of the recording and were recorded at a rate of 12 Fura-2 ratios s-1 (24 fps). For the rest 
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of the protocol, data was acquired at 0.2 Hz. E) Mean change in Fura-2 ratio before and after SFT-MI 
for 5G or 20G without (-) and with (+) Gö6976. F) Mean percentage of cells recovering transients at 
the end of the SFT-MI protocol for 5G and 20G without (-) and with (+) Gö 6976. (*P<0.05, **P<0.01, 
***P<0.001 Two-Way ANOVA with Holm-Šídák post-test). n≥87, ≥6 experiments, ≥3 animals for 
each data set. 
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Figure 10 
 
 
Figure 10: Fluorescent imaging with MgGreen and TMRM shows that Gö6976 attenuates the 
effect of 20G on ATP production and mitochondrial membrane potential in simulated ischaemia. 
Time-courses showing the MgGreen fluorescence (F/F0) from 4 cells, and mean data from 4 
experiments, throughout the SFT-MI protocol in 5G and 20G without (-; A) and with (+; B) Gö6976. 
C) Mean change in MgGreen fluorescence at the end of SFT-phase for 5G and 20G without (-) and with 
(+) Gö6976. (**P<0.01, ***P<0.001, Two-Way ANOVA with Holm-Šídák post-test). n≥29 
cardiomyocytes, ≥4 experiments from ≥4 animals for each data set. Time-courses showing the TMRM 
fluorescence (F/F0) from 4 cells, and mean data from 4 experiments, throughout the SFT-MI protocol 
in 5G and 20G without (-; D) and with (+; E) Gö6976. F) Mean change in TMRM fluorescence at the 
end of SFT-phase for 5G and 20G without (-) and with (+) Gö6976 (***P<0.001, Two-Way ANOVA 
with Holm-Šídák post-test). n≥41 cardiomyocytes, ≥4 experiments from ≥4 animals for each data set. 
Experimental design as shown in Figure 1. 
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Figure 11 
 
 
Figure 11: Time to KATP channel opening and development of a metabolically-sensitive leak-
current are delayed by Gö6976 in the presence elevated glucose. A) Example traces of cell-attached 
patch recording of rat cardiomyocytes showing the time to KATP channel opening during SFT-MI 
following 5 or 20 mM glucose in the absence and presence of Gö6976. B) Mean time to KATP channel 
opening during SFT-MI perfusion in all 4 conditions. C) Example traces of whole-cell patch recording 
displaying the leak current activated during SFT-MI perfusion in 5 and 20 mM glucose in the absence 
and presence of Gö6976. D) Mean time to increase in leak current during SFT-MI perfusion in all 4 
conditions (***P<0.001, Two-Way ANOVA with Holm-Šídák post-test). n≥8 cardiomyocytes, 
≥8experiments, ≥3 animals for each data set. Arrows indicate time=0, the point at which SMT-MI was 
perfused on to cardiomyocytes. 
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Figure 12 
 
Figure 12: Gö6976 and LY379196 impart cardioprotection when applied before simulated 
ischaemia or reperfusion. A) Time-course showing the percentage of contractile cardiomyocytes 
during SFT-MI protocol in the absence and presence of Gö6976 at the start of simulated ischaemia and 
reperfusion. Histograms showing percentage contractile recovery (B) and cell survival (C) after 10 min 
reperfusion in the absence and presence of Gö6976 at the time of simulated ischaemia and reperfusion. 
Graphs D-F show the results for LY379196. ***P<0.001, One-Way ANOVA with Holm-Šídák post-
test. n≥84 cardiomyocytes (6 experiments) from ≥3 animals for each data set. Experimental design used 
shown above the data.  
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Figure 13 
 
Figure 13: Gö 6976 and LY 379196 impart cardioprotection from the deleterious effects of 
elevated glucose at reperfusion. A) Time-course showing the percentage of contractile 
cardiomyocytes during I/R protocol with Gö 6976 or LY 379196 added at reperfusion in elevated 
glucose. Histograms showing percentage contractile recovery (B) and percentage cell survival after 10 
min reperfusion. n≥115 cardiomyocytes, n≥5 experiments n=3 animals for each data set. ***P<0.001, 
One-Way ANOVA with Holm-Šídák post-test. n≥74 cardiomyocytes (6 experiments) from ≥3 animals 
for each data set. Experimental design used shown above the data. 
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Figure 14 
 
 
Figure 14: Gö6976 imparts cardioprotection against glucose induced damage during whole heart 
coronary ligation. A) representative pictures showing the whole heart (from left to right) before and 
during ligation, reperfusion and Blue Evans staining. B) Representative sections for each condition 
showing the infract size as measured by of TTC staining (white), area at risk (red) and unaffected area 
(Blue). C) Histograms depict infarct as a percentage of the area at risk (Left) and percentage area at risk 
of the whole heart (Right) in each condition as a control for experimental variability. **P<0.01, 
OneWay ANOVA with Holm-Šídák post-test. n = 8 hearts for each group. 
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Figure 15 
 
Figure 15: The proposed mechanism of glycaemia-PKCα/β inhibition dependent cardioprotection 
against simulated ischaemia. 1) The underlying molecular mechanism(s) linking glucose-glycolytic 
metabolism-PKCα/β activation with myocardial damage remain unclear. 2) Enhanced glycolytic 
metabolism-PKCα/β activation caused early after depolarisations (EADs) and action potential duration 
(APD) variability. 3) Electrical instability resulted in a greater influx of Ca2+ into the cells. 4)  Prolonged 
ischaemia will result in mitochondrial depolarisation (ΔΨm) and so reduce ATP production. 5) In turn 
Ca2+ accumulates as there is not enough ATP to drive removal of Ca2+ via SERCA, PMCA or indirectly 
by NCX. 6) If ATP levels decrease sufficiently, the cardiac KATP channel activates and produce a large 
hyperpolarisation to reduce cell excitability. 7) As ischaemia conditions continue, enhanced glycolytic 
metabolism-PKCα/β activation increase in myocardial damage and reperfusion arrhythmias. The 
presence of PKCα/β inhibitors in high glucose preserved electrical function, reduced Ca2+ accumulation 
and so ATP consumption, whilst preserving mitochondrial membrane potential so ATP production. 
KATP activation was delayed, a marker of delayed ATP depletion, and the functional recovery was 
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improved on reperfusion. The colour red has been used to indicate potentially toxic changes with 
elevated glucose whilst blue indicates potentially protective mechanisms. 
